$IMNM
Immunome Inc.

2022 Q1 Form 10-Q Financial Statement

#000155837022008432 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.576M $1.920M
YoY Change 86.25%
% of Gross Profit
Research & Development $8.078M $1.979M
YoY Change 308.19% -6.43%
% of Gross Profit
Depreciation & Amortization $111.0K $176.0K
YoY Change -36.93% 7.98%
% of Gross Profit
Operating Expenses $11.65M $3.897M
YoY Change 199.05% 46.78%
Operating Profit -$11.65M -$3.897M
YoY Change 199.05% 46.78%
Interest Expense $1.000K $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$11.65M -$3.900M
YoY Change 198.79%
Income Tax
% Of Pretax Income
Net Earnings -$11.70M -$3.900M
YoY Change 200.0% 44.44%
Net Earnings / Revenue
Basic Earnings Per Share -$0.96 -$0.37
Diluted Earnings Per Share -$0.96 -$0.37
COMMON SHARES
Basic Shares Outstanding 12.12M 10.64M
Diluted Shares Outstanding 12.12M 10.64M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $42.88M $36.28M
YoY Change 18.19%
Cash & Equivalents $42.88M $36.28M
Short-Term Investments
Other Short-Term Assets $2.629M $4.830M
YoY Change -45.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $46.30M $41.11M
YoY Change 12.64%
LONG-TERM ASSETS
Property, Plant & Equipment $753.0K $1.386M
YoY Change -45.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $482.0K $100.0K
YoY Change 382.0%
Total Long-Term Assets $1.425M $1.486M
YoY Change -4.1%
TOTAL ASSETS
Total Short-Term Assets $46.30M $41.11M
Total Long-Term Assets $1.425M $1.486M
Total Assets $47.73M $42.59M
YoY Change 12.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.890M $2.958M
YoY Change 31.51%
Accrued Expenses $5.817M $1.169M
YoY Change 397.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $366.0K
YoY Change
Total Short-Term Liabilities $9.707M $4.571M
YoY Change 112.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $134.0K
YoY Change -100.0%
Other Long-Term Liabilities $147.0K $10.00K
YoY Change 1370.0%
Total Long-Term Liabilities $147.0K $134.0K
YoY Change 9.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.707M $4.571M
Total Long-Term Liabilities $147.0K $134.0K
Total Liabilities $9.854M $4.710M
YoY Change 109.21%
SHAREHOLDERS EQUITY
Retained Earnings -$90.80M -$58.30M
YoY Change 55.75%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.87M $37.88M
YoY Change
Total Liabilities & Shareholders Equity $47.73M $42.59M
YoY Change 12.06%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$11.70M -$3.900M
YoY Change 200.0% 44.44%
Depreciation, Depletion And Amortization $111.0K $176.0K
YoY Change -36.93% 7.98%
Cash From Operating Activities -$6.376M -$3.535M
YoY Change 80.37% 71.27%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $31.00K
YoY Change -80.65% -43.64%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.000K -$31.00K
YoY Change -80.65% -43.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $105.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 32.00K 76.00K
YoY Change -57.89% -91.0%
NET CHANGE
Cash From Operating Activities -6.376M -3.535M
Cash From Investing Activities -6.000K -31.00K
Cash From Financing Activities 32.00K 76.00K
Net Change In Cash -6.350M -3.490M
YoY Change 81.95% 173.73%
FREE CASH FLOW
Cash From Operating Activities -$6.376M -$3.535M
Capital Expenditures $6.000K $31.00K
Free Cash Flow -$6.382M -$3.566M
YoY Change 78.97% 68.29%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12122903
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10640870
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12127385
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12110373
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39580
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Immunome, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2022Q1 dei City Area Code
CityAreaCode
610
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2022Q1 dei Trading Symbol
TradingSymbol
IMNM
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12127385
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42879000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3424000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
46303000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56638000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
753000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
190000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q1 us-gaap Deferred Costs
DeferredCosts
382000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2022Q1 us-gaap Assets
Assets
47728000
CY2021Q4 us-gaap Assets
Assets
57925000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3890000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3077000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5817000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9707000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9728000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
147000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
12000
CY2022Q1 us-gaap Liabilities
Liabilities
9854000
CY2021Q4 us-gaap Liabilities
Liabilities
9740000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12127385
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12110373
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
128631000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127289000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90758000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79105000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37874000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
47728000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57925000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8078000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1979000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3576000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1918000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
11654000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
3897000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11654000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3897000
CY2022Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1000
CY2021Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11653000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12122903
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10640870
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1310000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11653000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
37874000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
325000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
105000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
37883000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11653000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3898000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
111000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
176000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
25000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1310000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
325000
CY2022Q1 imnm Deferred Rent
DeferredRent
-12000
CY2021Q1 imnm Deferred Rent
DeferredRent
-1000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3985000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1703000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
788000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1771000
CY2022Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-912000
CY2021Q1 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-205000
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-18000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6376000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3535000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
32000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2021Q1 imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
105000
CY2021Q1 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
35000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
76000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6350000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3490000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42979000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36376000
CY2022Q1 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
215000
CY2022Q1 imnm Stock Issuance Costs Included In Accounts Payable And Accrued Expenses And Other Liabilities Current
StockIssuanceCostsIncludedInAccountsPayableAndAccruedExpensesAndOtherLiabilitiesCurrent
25000
CY2022Q1 imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
25000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
3000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
2000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-11700000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-3900000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-90800000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42900000
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these condensed financial statements include, but are not limited to, the expected volatility used to estimate fair value of stock options and accrued research and development expenses. Estimates and assumptions are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42879000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
100000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42979000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
400000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3312956
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2659599
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
200000
CY2022Q1 us-gaap Prepaid Insurance
PrepaidInsurance
1422000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2019000
CY2022Q1 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
636000
CY2021Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
586000
CY2022Q1 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
795000
CY2021Q4 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
1638000
CY2022Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
571000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
492000
CY2021Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
2674000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3424000
CY2022Q1 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
3972000
CY2021Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2840000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
842000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1246000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
357000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000
CY2022Q1 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
585000
CY2021Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
2021000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
61000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2022Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
5817000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2021Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2022Q1 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2022Q1 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
CY2022Q1 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1310000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
325000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
12100000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.835
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.835
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.017
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2022Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
10.58
CY2021Q1 imnm Fair Value Of Common Stock
FairValueOfCommonStock
31.83

Files In Submission

Name View Source Status
0001558370-22-008432-index-headers.html Edgar Link pending
0001558370-22-008432-index.html Edgar Link pending
0001558370-22-008432.txt Edgar Link pending
0001558370-22-008432-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20220331.xsd Edgar Link pending
tmb-20220331x10q.htm Edgar Link pending
tmb-20220331x10q_htm.xml Edgar Link completed
tmb-20220331xex10d1.htm Edgar Link pending
tmb-20220331xex31d1.htm Edgar Link pending
tmb-20220331xex31d2.htm Edgar Link pending
tmb-20220331xex32d1.htm Edgar Link pending
tmb-20220331xex32d2.htm Edgar Link pending
tmb-20220331_cal.xml Edgar Link unprocessable
tmb-20220331_def.xml Edgar Link unprocessable
tmb-20220331_lab.xml Edgar Link unprocessable
tmb-20220331_pre.xml Edgar Link unprocessable